Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 11, 2009, Pages 1781-1787

  Zinzani, Pier Luigi ^a   Stefoni, Vittorio ^a   Tani, Monica ^a   Fanti, Stefano ^a   Musuraca, Gerardo ^a   Castellucci, Paolo ^a   Marchi, Enrica ^a   Fina, Mariapaola ^a   Ambrosini, Valentina ^a   Pellegrini, Cinzia ^a   Alinari, Lapo ^a   Derenzini, Enrico ^a   Montini, Giancarlo ^a   Broccoli, Alessandro ^a   Bacci, Francesco ^a   Pileri, Stefano ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER RELAPSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE RISK; CLINICAL TRIAL; COMPARATIVE STUDY; LYMPHOMA; PATHOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 64649086758     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1513     Document Type: Article

References (40)

1. Buchmann I, Reinhardt M, Eisner K, et al: 2- (Huorine-18)Huoro-2-deoxy-D- glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial. Cancer 91: 889-899, 2001
2. Hutchings M, Eigtved Ali Specht L: FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52:19-32, 2004
3. Hutchings M, Loft A, Hansen M, et al: Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489, 2006
4. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266-273, 2001
5. Menzel C, Dobert N, Mitrou P, et al: Positron emission tomography for the staging of Hodgkin's lymphoma: Increasing the body of evidence in favor of the method. Acta Onco1 41:430-436, 2002
6. Wirth A, Seymour F, Hicks R, et al: Fluorine-18 huorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, a conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112:262-268, 2002
7. Kostakoglu L, Leonard P, Coleman M, et al: The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol 2:115-121, 2004
8. Sasaki M, Kuwabara Y, Koga H, et al: Clinical impact ot whole body FDG-PET on the staging and therapeutic decision making for malignant lym- phoma. Ann Nucl Med 16:337-345, 2002
9. Schöder H, Meta, Yap C, et al: Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42:1139-1143, 2001
10. Weihrauch MR, Re D, Bischoff S, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglueose for initial staging of patients with Hodgkin's disease. Ann Hematol 81:20-25, 2002
11. Schiepers C, Filmont E, Czernin J: PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30:S82- S88, 2003 (suppl 1)
12. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
13. Zinzani PL, Musuraca G, Alinari L, et al: Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7:291-295, 2007
14. Blum RH, Seymour JF, Wirth A, et al: Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4:43-49, 2003
15. Cheson BD, Horning SI, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's Iymphomas. J Clin Oncol 17:1244-1253, 1999
16. Lister TA, Crowher D, Sutcliffe SE, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
17. Lavely WC, Delbeke D, Creer JP, et al: FDC PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin Iymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 57:307-315, 2003
18. Jerusalem G, Warland V, Najjar F, et al: Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 20:13-20, 1999
19. Spaepen K, Stroobants S, Dupont P, et al: Can positron emission tomography with [(18)F]- fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278, 2001
20. Zijlstra JM, Lindauer-van deI Werf C, Hoekstra OS, et al: 18F-fluoro-deoxyglueose positron emission tomography for post-treatment evaluation of malignant Iymphoma: A systematic review. Haematologica 91:522-529, 2006
21. Zinzani PL, Musuraca G, Alinari L, et al: Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7:291-295, 2007
22. Zinzani PL, Chierichetti F, Zompatori M, et al: Advantages of positron emission tomography (PET) with respect to computer tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 43:1239-1243, 2002
23. Zinzani PL, Fanti S, Battista G, et al: Predictive role of positron emission tomography PET in the outcome of lymphoma patients. Br J Cancer 91:850-854, 2004
24. Gallamini A, Rigacci L, Merli F, et al: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91:475-481, 2006
25. Hutchings M, Mikhaeel NC, Fields FA, et al: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin Iymphoma. Ann Oncol 16:1160-1168, 2005
26. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Iymphoma. Blood 107:52-59, 2006
27. Kostakoglu l, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
28. Zinzani PL, Tani M, Fanti S, et al: Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 17:1296-1300, 2006
29. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al: 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: Comparison with CT. Leuk Lymphoma 39:543-553, 2000
30. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplasm of the hematopoietic and lymphoid tissue: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hema-tol J 1:53-66, 2000
31. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
32. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
33. Radford JA, Eardley A, Woodman C, et al: Follow-up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 314:343-346, 1997
34. Torrey MJ, Poen JC, Hoppe RT: Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 15:1123-1130, 1997
35. Spaepen K, Stroobants S, Verhoef G, et al: Positron emission tomography with (18F)FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Imaging 30:S97-S105, 2003 (suppl 1)
36. Jerusalem G, Beguin Y, Fassotte MF, et al: Early detection of relapse by whole-body emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130, 2003
37. Rhodes MM, Delbeke D, Whitlock JA, et al: Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28:300-306, 2006
38. Levine JM, Weiner M, Kelly KM: Routine use of PET scans after completion of therapy in pedriatric Hodgkin disease: Results in a high false positive rate. J Pediatr Hematol Oncol 28:711-714, 2006
39. Castellucci P, Zinzani PL, Pourdehnad M, et al: 18F-FDG PET in malignant lymphoma: Significance of positive findings. Eur J Nucl Med Mol Imaging 32:749-756, 2005
40. Mikhaeel NG, Hutchings M, Fields PA, et al: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high- grade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523, 2005